Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol

Research output: Contribution to journalArticle

1 Citation (Scopus)


Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalActa Medica Okayama
Issue number3
Publication statusPublished - Jan 1 2018



  • Cisplatin
  • Furosemide
  • Hydration
  • Lung cancer
  • Mannitol
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this